CA-ASM-GLOBAL
3.3.2022 13:02:16 CET | Business Wire | Press release
ASM Global, the world’s leading venue management company and producer of live experiences, has been selected to manage Olympia London—as it undergoes a dramatic transformation as the premier exhibition centre in central London and one of Europe’s most historic venues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220303005466/en/
The announcement is a critical step in the redevelopment of Olympia London and will see ASM Global take management responsibility for the exhibitions and events business. The move expands ASM’s footprint in Europe with an iconic London venue and brings global knowledge-sharing to expand Olympia London’s international market reach.
Olympia’s redevelopment, which will be completed in 2024, includes a 4,400-capacity live-music venue; a 1,575-seat performing arts theatre; a school for the creative arts; 100,000 sq. ft of restaurants, bars and eateries; two globally renowned hotels; 550,000 sq. ft. of offices; and 2.5 acres of new public space.
ASM Global and Olympia London’s management teams have begun collaborating on venue enhancement plans for the reimagined world-class conference and hospitality facilities.
Olympia London has been a cultural and architectural landmark since opening its doors in 1886. Today, it is one of London’s busiest venues and in recent years has attracted more than 1.6 million visitors and hosted over 200 events each year. The overall Olympia site is currently being redeveloped as a cultural district—a new destination for art, culture, education, entertainment, exhibitions, music, state-of-the-art offices, and some of the best food and drink in town.
ASM Global president and CEO Ron Bension said, “We are proud to partner with Olympia London, Yoo Capital and Deutsche Finance International on this amazing and historic venue, positioning it at the forefront of the industry for the next 100 years. Our commitment to guest and partner satisfaction aligns with the reputation of Olympia London, and we look forward to continuing to serve existing and new clients’ event schedules at Olympia London and developing the program with other signature events.”
ASM Global has an unrivalled track record working with major cultural and entertainment districts and venues, including L.A. LIVE in Los Angeles, Darling Harbour in Sydney, OVO Arena Wembley in London and AO Arena Manchester. ASM will leverage its global relationships in content, programming, planning, technology, sustainability and guest safety to further enhance the visitor experience at Olympia London.
Olympia London joins ASM Global’s network of more than 300 venues around the world, which host 20,000 events and welcome 165 million guests every year. Other flagship exhibition and convention centres in its portfolio include McCormick Place in Chicago, Moscone Center in San Francisco, ICC Sydney, Shenzhen World in China and P&J Live in Aberdeen, U.K.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 325 of the world’s most prestigious arenas, stadiums, convention and exhibition centres, and performing arts venues. Follow us on Facebook , Instagram and Twitter or visit asmglobal.com .
About Olympia London
From breath-taking consumer shows and thrilling sporting and music events, to colourful trade shows, Olympia London is the home of inspirational events. Located in the heart of London, its atmosphere, distinctive architecture and 136-year heritage are a magnet for the best and boldest events in the U.K. The venue is a leader in sustainability. One of the founders and the first venue to achieve certification to the event sustainability management system international standard, ISO 20121, it has sent zero waste to landfill for over a decade. In 2021, Olympia London was one of the first U.K. event businesses to commit to Net Zero emissions by 2050 . Olympia London will soon be part of a larger destination for arts, culture and entertainment. This new creative district will boost the London economy with spaces for performing arts, live music, eating and drinking, hotels, co-working, and beautiful open spaces for everyone to enjoy. You’ve seen our history. Now, take a look at our future: olympia.london/future
About Olympia
Olympia—a destination with a taste for the spectacular—uniting art, entertainment, technology and the creative industries. Designed by Heatherwick Studio and SPPARC Architecture, the rejuvenation of the capital’s busiest events venue—which attracts more than 1.6 million visitors each year—sees the addition of five live entertainment venues, two globally renowned hotels, 40+ restaurants and eateries, an art-house cinema, creative offices and studios, and 2.5 acres of gardens and public realm. You can read more about the plans at olympia.co.uk , as well as the importance of sustainability to the development, in our ESG policy .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005466/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
